MX2023011339A - Anticuerpos anti-tau y usos de estos. - Google Patents

Anticuerpos anti-tau y usos de estos.

Info

Publication number
MX2023011339A
MX2023011339A MX2023011339A MX2023011339A MX2023011339A MX 2023011339 A MX2023011339 A MX 2023011339A MX 2023011339 A MX2023011339 A MX 2023011339A MX 2023011339 A MX2023011339 A MX 2023011339A MX 2023011339 A MX2023011339 A MX 2023011339A
Authority
MX
Mexico
Prior art keywords
antibodies
tau antibodies
tau
tauopathies
phf
Prior art date
Application number
MX2023011339A
Other languages
English (en)
Inventor
Rupesh Nanjunda
Kolen Kristof Van
Original Assignee
Janssen Biotech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Biotech Inc filed Critical Janssen Biotech Inc
Publication of MX2023011339A publication Critical patent/MX2023011339A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/577—Immunoassay; Biospecific binding assay; Materials therefor involving monoclonal antibodies binding reaction mechanisms characterised by the use of monoclonal antibodies; monoclonal antibodies per se are classified with their corresponding antigens
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Psychiatry (AREA)
  • Genetics & Genomics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biophysics (AREA)
  • Hospice & Palliative Care (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Se describen anticuerpos monoclonales anti-PHF-tau y fragmentos de unión al antígeno de estos; además, se describen ácidos nucleicos que codifican los anticuerpos, composiciones que comprenden los anticuerpos, métodos para producir los anticuerpos y usar los anticuerpos para tratar o prevenir afecciones, tales como tauopatías.
MX2023011339A 2021-03-26 2022-03-25 Anticuerpos anti-tau y usos de estos. MX2023011339A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163166439P 2021-03-26 2021-03-26
US202163196365P 2021-06-03 2021-06-03
PCT/IB2022/052765 WO2022201123A1 (en) 2021-03-26 2022-03-25 Anti-tau antibodies and uses thereof

Publications (1)

Publication Number Publication Date
MX2023011339A true MX2023011339A (es) 2023-12-14

Family

ID=81326915

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2023011339A MX2023011339A (es) 2021-03-26 2022-03-25 Anticuerpos anti-tau y usos de estos.

Country Status (12)

Country Link
US (1) US20240150451A1 (es)
EP (1) EP4314048A1 (es)
JP (1) JP2024512589A (es)
KR (1) KR20230162790A (es)
AU (1) AU2022242135A1 (es)
BR (1) BR112023019546A2 (es)
CA (1) CA3214310A1 (es)
IL (1) IL307170A (es)
MX (1) MX2023011339A (es)
TW (1) TW202304974A (es)
UY (1) UY39699A (es)
WO (1) WO2022201123A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116925217B (zh) * 2023-09-14 2024-03-08 北京凯祥弘康生物科技有限公司 针对Tau蛋白的抗体
CN116948024B (zh) * 2023-09-14 2024-02-06 北京凯祥弘康生物科技有限公司 抗Tau蛋白的捕获抗体

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
SI2794654T1 (sl) * 2011-12-20 2019-08-30 Janssen Biotech, Inc. Protitelesa proti PHF-tau njihove uporabe
WO2014008404A1 (en) 2012-07-03 2014-01-09 Washington University Antibodies to tau
CN108602762B (zh) * 2016-01-29 2022-12-16 贝兰迪克有限责任公司 接头分子及其在纯化肽的方法中的用途
JOP20180021A1 (ar) 2017-03-16 2019-01-30 Janssen Biotech Inc الأجسام المضادة لتكتلات خيوط بروتين تاو (tau) الحلزونية المزدوجة واستخداماتها
CA3093200A1 (en) 2018-03-05 2019-09-12 Janssen Pharmaceutica Nv Anti-phf-tau antibodies and uses thereof
US20210270847A1 (en) * 2018-08-17 2021-09-02 University Of Florida Research Foundation, Incorporated Protein and peptide biomarkers for traumatic injury to the central nervous system

Also Published As

Publication number Publication date
UY39699A (es) 2022-09-30
WO2022201123A1 (en) 2022-09-29
EP4314048A1 (en) 2024-02-07
AU2022242135A1 (en) 2023-11-09
US20240150451A1 (en) 2024-05-09
TW202304974A (zh) 2023-02-01
JP2024512589A (ja) 2024-03-19
IL307170A (en) 2023-11-01
CA3214310A1 (en) 2022-09-29
KR20230162790A (ko) 2023-11-28
BR112023019546A2 (pt) 2023-10-31

Similar Documents

Publication Publication Date Title
PH12019501973A1 (en) Anti-phf-tau antibodies and uses thereof
MX2020009366A (es) Anticuerpos anti-cd73 y usos de los mismos.
PH12020552010A1 (en) Anti-cd33 antibodies, anti-cd33/anti-cd3 bispecific antibodies and uses thereof
ZA202004730B (en) Anti-claudin 18.2 antibodies and uses thereof
CR20220505A (es) Anticuerpos anti-phf-tau y usos de estos
MX2020011914A (es) Anticuerpos anti-dll3 y usos de los mismos.
MX2023011339A (es) Anticuerpos anti-tau y usos de estos.
PH12020551373A1 (en) Anti-phf-tau antibodies and uses thereof
WO2021212049A3 (en) Anti-sars-cov-2 monoclonal antibodies
MX2020009522A (es) Anticuerpos anti-folato del receptor 1 y usos de los mismos.
MX2021004454A (es) Anticuerpos anti-sinucleina.
MY193821A (en) Humanized antibody for treating or preventing cognitive disorders, process for producing the same, and agent for treating or preventing cognitive disorders using the same
MX2021012962A (es) Anticuerpo monoclonal que se une especificamente a gitr.
MX2023004869A (es) Anticuerpos contra sars-cov-2 y usos de los mismos.
MX2022010664A (es) Materiales y métodos para modular una respuesta inmunitaria.
CR20230581A (es) Anticuerpos anti-CCR8 y usos de los mismos
MX2023002948A (es) Métodos y composiciones para modular la inmunidad mediada por cadena beta.
MX2022015966A (es) Anticuerpos y metodos para tratar enfermedades asociadas a claudina.
CR20210548A (es) Materiales y métodos para modular la inmunidad mediada por células t
PH12020500662A1 (en) Anti-pfrh5 antibodies and antigen-binding fragments thereof
AU2018345715A8 (en) DNA monoclonal antibodies targeting CTLA-4 for the treatment and prevention of cancer
EA202092122A1 (ru) Антитела против tip-1 и их применения
MX2022013920A (es) Anticuerpos anti-antigeno asociado con tumor y usos de los mismos.
MX2022007513A (es) Anticuerpos biespecificos con cisteinas intercatenarias apareadas alternativamente y sus usos.
MX2023011340A (es) Anticuerpos humanizados contra el filamento helicoidal emparejado tau y usos de estos.